As per the latest study by Market Research Future (MRFR), the global migraine market will show a promising growth in the future and is expanding at a lucrative growth rate during the forecast period (2013-2022). This lavish growth pattern of the market is the result of the rising disease prevalence, lifestyle changes, development of novel therapies, and increasing consumption of hormonal medications.
Growth Drivers and Top Barriers
October 2018 – According to recent reports, many of those afflicted by migraine will now be able to get their hands on an oral CGRP drug whenever needed. Al¬ler¬gan is in the process of filing for FDA ap-proval for ubro¬gepant, which will make the process of treating migraine even faster. This example points towards the continuously increasing uptake of novel drug classes, such as ditans, gepants, and reformulation of triptans that can be used for both episodic and chronic migraine. Moreover, the multi-billion-dollar market is also benefitting from the strong research and development (R&D) that is resulting in the emergence of CGRP-based therapies.
Get Free Sample Copy of “Migraine market” @ https://www.marketresearchfuture.com/sample_request/2381
The fact is that migraine affects women more than men, with 17% women having reported a migraine attack compared to 6% men, every year. Migraine can be described as a debilitating neurological disease, wherein the affected person suffers from recurrent attacks of extreme throbbing head pain, lasting for about three days or more. The pain can get worse on movement, which prevents the patient from carrying out day-to-day activities, affecting both the sides of the head, face, or the neck.
At present, the treatment paradigm for migraine prevention has drastically evolved with the launch of Amgen/ Novartis’ CGRP mAb Aimovig as well as Teva Pharma’s Ajovy, setting the pace for more types of drug therapies. There are numerous drug manufacturers that are slated to make an entry into the market by 2019, such as Alder BioPharma, Biohaven Pharma and Eli Lilly, with the key differentiating factor being the prices of the product. Moreover, the migraine drugs and the CGRP-based therapies are noted to have a similar safety profile as well as efficacy.
Few of the most renowned players in the Migraine Market are
- Abbott Laboratories Inc.,
- GlaxoSmithKline plc.,
- Eisai Inc.,
- Impax Laboratories,
- Pfizer, Inc.,
- Johnson & Johnson,
- AstraZeneca plc,
- Kowa Pharmaceuticals America,
- Eli Lilly and Company,
- Meda, Merck,
- Luitpold Pharmaceuticals
October 2018 Three types of medication introduced by three companies have recently been approved by the U.S. Food and Drug Administration (FDA). The drugs help block the action of a protein fragment known as calcitonin gene-related peptide (CGRP). These migraine-inhibiting drugs are fremanezumab (Ajovy), erenumab (Aimovig) and the third being galcanezumab which has been introduced by Eli Lilly.
Eli Lilly’s Lasmiditan and Allergan’s ubrogepant are going to be first-in-class migraine drugs that boast of novel mechanism of actions for those that are unresponsive to triptans or are at risk of cardiovascular disorders. Many types of triptans that are under the late-stage development have reformulation of generic triptans, which help improve the efficiency of the existing formulations.
In addition, Zosano Pharma’s M207 is now being analyzed in Phase III ADAM (NCT03282227) trial, with the drug being a novel formulation of zolmitriptan. The drug can be delivered via Zosano’s proprietary Adhesive Dermally Applied Microarray (ADAM) technology. These ongoing tests and trials help improve the productivity and efficacy of the drugs that can help mitigate the drastic symptoms and signs of migraine, leaving a positive impact on the growth of the market in the coming years.
The global migraine market has been segmented on the basis of types, treatment types and drug class.
The types of migraine are episodic and chronic.
The market, based on the treatment types, can be classified into preventive and abortive.
Lastly, on the basis of drugs, the market is considered for triptans, ergots and others. The majority of these drugs have been approved for the acute form of migraine, led by triptans as the first-line treatment. Furthermore, all of these drugs follow disease-altering approaches, and boast of superior clinical efficacy as well as excellent safety profile, which elevate their demand in the market for the treatment of migraine.
Access Full Report Details and Order this Premium Report @ https://www.marketresearchfuture.com/reports/migraine-market-2381
The migraine market is spread across the prominent regions of Asia Pacific, North America, Europe and the rest of the world (RoW).
Migraine has been reported to be the third most prevalent and the sixth most disabling illnesses across the globe, with over 37 million in the United States (U.S.) alone. In North America, U.S. is the dominating country, with more than 65% share of the global market. It is projected to maintain its lead throughout the review period. Besides, the regional market will profit largely due to the launch of CGRP based therapies, increasing adoption of novel therapeutics, as well as a massive target population in the United States.
On the other hand, developing markets in Asia Pacific depict a healthy growth as well, on account of the increasing expenditure on healthcare, low-cost production of drugs, growing disease awareness and a large underserved patient population in the region.
Increasing stress levels, changing lifestyles, and growing prevalence of hormonal imbalance are leading to migraine, which is inducing strong demand for proper medication. These factors have been highly responsible for the burgeoning market size in Europe over the past few years.